{
    "organizations": [],
    "uuid": "1d7868a4df0bd33d58bb2bb49342677a3e0f925a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aimmune-extends-supply-agreement-w/brief-aimmune-extends-supply-agreement-with-golden-peanut-and-tree-nuts-for-experimental-allergy-treatment-idUSASB0C0IJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS INC - ‍NEWLY EXPANDED GLOBAL AGREEMENT SECURES EXCLUSIVE SUPPLY RELATIONSHIP THROUGH 2033​\n* AIMMUNE THERAPEUTICS INC - AR101 IS CURRENTLY IN PHASE 3 CLINICAL TRIALS, WITH PIVOTAL TOPLINE DATA EXPECTED IN FEBRUARY\n* AIMMUNE THERAPEUTICS INC - ‍AS PART OF AGREEMENT, AIMMUNE HAS GRANTED ADM A 300,000-SHARE EQUITY STAKE IN AIMMUNE​\n* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS - ‍ AGREEMENT GIVES CO EXCLUSIVE ACCESS TO ADDITIONAL GOLDEN PRODUCTS THAT COULD BE DEVELOPED INTO PEANUT ORAL IMMUNOTHERAPIES​ ",
    "published": "2018-01-10T21:03:00.000+02:00",
    "crawled": "2018-01-11T12:41:45.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aimmune",
        "therapeutic",
        "inc",
        "aimmune",
        "therapeutic",
        "broadens",
        "extends",
        "supply",
        "agreement",
        "golden",
        "peanut",
        "tree",
        "nut",
        "ar101",
        "peanut",
        "allergy",
        "aimmune",
        "therapeutic",
        "inc",
        "expanded",
        "global",
        "agreement",
        "secures",
        "exclusive",
        "supply",
        "relationship",
        "aimmune",
        "therapeutic",
        "inc",
        "ar101",
        "currently",
        "phase",
        "clinical",
        "trial",
        "pivotal",
        "topline",
        "data",
        "expected",
        "february",
        "aimmune",
        "therapeutic",
        "inc",
        "part",
        "agreement",
        "aimmune",
        "granted",
        "adm",
        "equity",
        "stake",
        "aimmune",
        "therapeutic",
        "broadens",
        "extends",
        "supply",
        "agreement",
        "golden",
        "peanut",
        "tree",
        "nut",
        "ar101",
        "peanut",
        "allergy",
        "aimmune",
        "therapeutic",
        "agreement",
        "give",
        "co",
        "exclusive",
        "access",
        "additional",
        "golden",
        "product",
        "could",
        "developed",
        "peanut",
        "oral"
    ]
}